Tasly Healthcare

Since 2019 we have been strategic contractual partner of Tasly Healthcare Deutschland GmbH, Hanover, for the provision of pharmaceutical regulatory services such as quality assurance for GMP, GCP, GLP for pharmaceuticals in the European Union. Tasly Holding Group, Ltd., Tianjin, China is a Chinese health group. Tasly was the first company to successfully complete an FDA Phase III for a combination phytopharmaceutical used in Chinese medicine. The partly publicly listed Chinese health group with around 25,000 employees worldwide and annual sales of around 4 billion euros is one of the market leaders for traditional Chinese medicine in China. On the other hand, he is active in classical western medicine, for example, licensing insulin production and running pharmacies and hospitals in China. In addition, the health group holds stakes in global technology start-ups, such as the US sensor technology company Profusa, near Silicon Valley, the AI company AiTreat from Singapore, and the Australian stem cell company Mesoblast.

Ministry & Health Economy Mecklenburg-Vorpommern
BioCon Valley e.V.

Not least because our pharmaceutical site is located in the Bioeconomy Innovation Center in Mecklenburg-Vorpommern, we are in an exchange with the Minister of Health and Economics of the German Federal State of Mecklenburg-Vorpommern on various topics of the health economy and bioeconomy, as here with our Chinese contract partner Tasly in 11 / 2019.

In 08/2020 we submitted the membership application for admission to the

BioCon Valley e.V., through the Fortis Pharma GmbH shareholder Recoga GbR.